ReviewJournal of neural transmission (Vienna, Austria : 1996)2018
90 years of monoamine oxidase: some progress and some confusion.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Development of 1-(substituted benzofuran-2-yl)-3-(halogen-substituted phenyl)prop-2-en-1-ones as potent, reversible, and selective MAO-B inhibitors for Parkinson's Disease.Scientific reports · 2026Article
- Novel Insights on Benzo[Antioxidants (Basel, Switzerland) · 2026Article
- Dehydrogenases in the Flavoprotein Amine Oxidoreductase Superfamily.Biochemistry · 2025Article
- Development of 5-phenylnitro bearing furan-based chalcones as a new class of potent MAO-B inhibitors.Future medicinal chemistry · 2025Article
- Type A monoamine oxidase; its unique role in mood, behavior and neurodegeneration.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Fading Blue: Exploring the Causes of Locus Coeruleus Damage Across the Lifespan.Antioxidants (Basel, Switzerland) · 2025Review
- Optimizing Linezolid: Transforming It into a Selective MAO-B Inhibitor via a Toxicity-to-Activity Optimization Approach.ACS medicinal chemistry letters · 2025Article
- Neuropeptide inactivation regulates egg-laying behavior to influence reproductive health in Caenorhabditis elegans.Current biology : CB · 2024Article
- Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Effect of Hydroxytyrosol Derivatives of Donepezil on the Activity of Enzymes Involved in Neurodegenerative Diseases and Oxidative Damage.Molecules (Basel, Switzerland) · 2024Article
- Article
- A Comprehensive Review of the Docking Studies of Chalcone for the Development of Selective MAO-B Inhibitors.CNS & neurological disorders drug targets · 2024Review
- Integrative Omics Analysis Reveals Metabolic Features of Ground-Glass Opacity-Associated Lung Cancer.Journal of Cancer · 2024Article
- Monoamine oxidase mediated oxidative stress: a potential molecular and biochemical crux in the pathogenesis of obesity.Molecular biology reports · 2023Review
- From Monoamine Oxidase Inhibition to Antiproliferative Activity: New Biological Perspectives for Polyamine Analogs.Molecules (Basel, Switzerland) · 2023Article
- Inhibition of MAOB Ameliorated High-Fat-Diet-Induced Atherosclerosis by Inhibiting Endothelial Dysfunction and Modulating Gut Microbiota.Nutrients · 2023Article
- The SARS-CoV-2 spike glycoprotein interacts with MAO-B and impairs mitochondrial energetics.Current research in neurobiology · 2023Article
- Privileged multi-target directed propargyl-tacrines combining cholinesterase and monoamine oxidase inhibition activities.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Resveratrol Analogues as Dual Inhibitors of Monoamine Oxidase B and Carbonic Anhydrase VII: A New Multi-Target Combination for Neurodegenerative Diseases?Molecules (Basel, Switzerland) · 2022Article
- Design, Synthesis, and Monoamine Oxidase B Selective Inhibitory Activity ofACS medicinal chemistry letters · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It would not be practical to attempt to deal with all the advances that have informed our understanding of the behavior and functions of this enzyme over the past 90 years. This account concentrates key advances that explain why the monoamine oxidases remain of pharmacological and biochemical interest and on some areas of continuing uncertainty. Some issues that remain to be understood or are in need of further clarification are highlighted.
Indexed as
Identifiers
29637260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.